Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Sells $275,871.96 in Stock

by · The Cerbat Gem

Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) CTO Seshu Tyagarajan sold 31,278 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $8.82, for a total transaction of $275,871.96. Following the transaction, the chief technology officer now owns 85,512 shares of the company’s stock, valued at approximately $754,215.84. This represents a 26.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Seshu Tyagarajan also recently made the following trade(s):

  • On Wednesday, January 15th, Seshu Tyagarajan sold 14,322 shares of Candel Therapeutics stock. The shares were sold at an average price of $7.22, for a total transaction of $103,404.84.

Candel Therapeutics Stock Up 0.9 %

Candel Therapeutics stock traded up $0.08 during mid-day trading on Wednesday, hitting $8.90. 640,009 shares of the stock were exchanged, compared to its average volume of 2,651,855. The firm’s fifty day simple moving average is $8.23 and its two-hundred day simple moving average is $6.98. Candel Therapeutics, Inc. has a 12 month low of $1.40 and a 12 month high of $14.60. The stock has a market capitalization of $289.04 million, a price-to-earnings ratio of -5.14 and a beta of -1.29.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.17). As a group, analysts forecast that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Baker BROS. Advisors LP acquired a new stake in Candel Therapeutics during the fourth quarter worth approximately $25,884,000. Acorn Capital Advisors LLC bought a new position in shares of Candel Therapeutics during the 4th quarter worth approximately $16,836,000. Braidwell LP acquired a new stake in Candel Therapeutics in the fourth quarter worth $13,888,000. Portolan Capital Management LLC acquired a new stake in Candel Therapeutics in the fourth quarter worth $6,543,000. Finally, Halter Ferguson Financial Inc. increased its stake in Candel Therapeutics by 123.7% in the fourth quarter. Halter Ferguson Financial Inc. now owns 681,334 shares of the company’s stock valued at $5,914,000 after purchasing an additional 376,795 shares in the last quarter. 13.93% of the stock is owned by institutional investors.

Analyst Ratings Changes

CADL has been the subject of a number of research reports. Bank of America initiated coverage on Candel Therapeutics in a research note on Friday, February 7th. They issued a “buy” rating and a $15.00 price target for the company. Canaccord Genuity Group lifted their price target on Candel Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Candel Therapeutics in a research note on Friday, March 14th. Finally, Citigroup initiated coverage on shares of Candel Therapeutics in a report on Thursday, February 20th. They set a “buy” rating and a $25.00 target price on the stock.

Get Our Latest Stock Analysis on Candel Therapeutics

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

Recommended Stories